Safe Orthopaedics announces the 20,000th kit sold and the success of the evaluation phase of Sycamore
25 November 2021 - 6:37PM
Safe Orthopaedics announces the 20,000th kit sold and the success
of the evaluation phase of Sycamore
Safe
Orthopaedics announces the 20,000th kit sold and the success of the
evaluation phase of Sycamore
- 11,500 surgeries performed in France
- Success of the evaluation phase of the new vertebral
compression fracture (VCF) treatment, Sycamore
|
|
|
|
Éragny-sur-Oise,
Fleurieux-sur-l'Arbresle, November 25, 2021 at 5:45 pm CET
- Safe Orthopaedics (FR0013467123 - ALSAF), a company specializing
in the design, manufacture and marketing of ready-to-use
technologies for back surgery, particularly safe for
emergency-treated vertebral fractures, announces the 20,000th kit
sold, and the success of the evaluation phase of Sycamore, the
novel vertebral compression fracture (VCF) treatment.
Firstly, Safe Orthopaedics has successfully
reached the significant mark of 20,000 instrument kits sold across
the globe. With this achievement many patients have been
successfully treated using Safe Orthopaedics’ proprietary
ready-to-use technology that delivers significant benefits to the
hospital, the surgical team, and the patient.
On this topic, Nik Beyer, Chief Commercial
Officer of Safe Orthopaedics says: “Despite significant market
headwinds I’m delighted that through the hard work and
determination of our direct sales teams, distribution partners and
support teams we have continued to prove that there is a real, and
growing, un-met need for our ready-to-use technology in the global
spine market.”
Secondly, through close collaboration with
surgeons in France and Germany, Safe Orthopaedics is coming to the
end of a successful evaluation phase for its novel vertebral
compression fracture (VCF) treatment, Sycamore. With the
completion of this phase Sycamore is ready for launch early 2022 in
select markets.
Nik Beyer comments: “Sycamore is an exciting
product for our portfolio, a new concept to the market that
promises to deliver significant growth through 2022 and beyond in a
VCF market that continues to show year-on-year growth. Market
trends showed us that the solutions available to surgeons to manage
these hard-to-treat patients do not always achieve the best
results, Sycamore is designed to meet those demands”.
Pierre Dumouchel, CEO & Chairman of Safe
Group concludes: “It’s with great pride that we make this
announcement today. Our focus has always been on delivering the
best possible outcome for patients and it’s a privilege to have
contributed to the optimal treatment of so many patients. To
deliver this milestone in tough market conditions, during a
pandemic, and follow-up with a major piece of product development
in Sycamore is testament to the investment we have made in both our
commercial and innovation business units and the close working
partnerships we have with our expert surgeons. For VCF
patients, a long-term correction of the fracture is key to
delivering the best patient outcome. Our Sycamore implant is
designed to deliver exactly that”.
About Safe GroupSafe Group is a
French medical technology group that brings together Safe
Orthopaedics, a pioneer in ready-to-use technologies for spine
pathologies, and Safe Medical (formerly LCI Medical), a
subcontractor of medical devices for orthopedic surgery. The group
employs approximately 150 people.
Safe Orthopaedics develops and manufactures kits
combining sterile implants and single-use instruments, available at
any time to the surgeon. These technologies are part of a minimally
invasive approach aimed at reducing the risk of contamination and
infection, for the benefit of the patient and with a positive
impact on hospitalization times and costs. Protected by 18
patent families, SteriSpineTM kits are CE marked and FDA approved.
Safe Orthopaedics is headquartered in the Paris region
(Eragny-sur-Oise (95610)) and has subsidiaries in the United
Kingdom, Germany, the United States and the Lyon region
(Fleurieux-sur-l'Arbresle).
For more information:
www.safeorthopaedics.com
Safe Medical produces implantable medical
devices and ready-to-use instruments. It has an innovation centre
and two production sites in France (Fleurieux-sur-l'Arbresle,
69210) and Tunisia, offering a wide range of industrial services:
design, industrialisation, machining, finishing and sterile
packaging. Supported by the French recovery plan in 2020, the
company invests in additive printing and will be operational in
2022 on this new technology.
For more information: www.safemedical.fr
Contacts
Safe
Orthopaedics
François-Henri Reynaud
Chief Financial and Administrative Officer
Tél. : +33 (0)1 34 21 50
00
investors@safeorthopaedics.com
Press RelationsUlysse
CommunicationPierre-Louis Germain / +33 (0)6 64 79
97 51 / plgermain@ulysse-communication.comBruno
Arabian / +33 (0)6 87 88 47 26 /
barabian@ulysse-communication.com
- PR- 20 000 kits Sycamore vdef
SAFE (EU:ALSAF)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
SAFE (EU:ALSAF)
Historical Stock Chart
Von Jul 2023 bis Jul 2024